ArticleJournal of hepatocellular carcinoma2017

Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.

Marina G Tarakanovskaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.